- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
- Researchers develop tumor "avatar" model that predicts immunotherapy response with 93% accuracyResearchers at Elephas Biosciences, in collaboration with academic centers, created an ex vivo tumor "avatar" from patient biopsies to test how tumors respond to immunotherapy. They exposed 124 tu…